You work at Merck & Company (MRK), a well-known pharmaceutical company. Part of your job is to complete business case analyses for different drugs under development. One day, you are assigned to complete an analysis on a drug that has, so far, shown great promise for treating pancreatic cancer. After completing your revenue forecast under the assumption that the drug passes its next round of testing, you know that you need to discount those cash flows to find the present value. The drug isn't the most risky project the company has ever tried to produce, but it also is not the least risky. You decide that the best way to treat these cash flows is as if the drug was an average risk project for the firm. Is the WACC the appropriate discount rate to use for this project? Why or why not?
Now calculate the following using the publicly-available information below. | ||||
WACC: _______________________________ | ||||
MRK common stock beta: | 0.6 | |||
YTM on 10-year US Treasury bond: | 3.12% | |||
Average annual return on Vanguard Total Market Fund: | 10.55% | |||
Current MRK price per common share: | $73.81 | |||
Number of MRK common shares outstanding (in millions): | 2,678 | |||
Corporate tax rate: | 21% | |||
The company has the following long-term debt outstanding. (Assume this is the only debt the firm has.) | ||||
Bond issue | Coupon Rate | Book Value (in millions $) |
Market Price Quote (per bond) | YTM |
2.75% notes due 2025 | 2.750% | 2,488 | 94.8400 | 3.7100% |
3.70% notes due 2045 | 3.700% | 1,973 | 90.9900 | 4.3200% |
2.80% notes due 2023 | 2.800% | 1,744 | 97.1700 | 3.5100% |
5.00% notes due 2019 | 5.000% | 1,260 | 101.1400 | 3.2800% |
4.15% notes due 2043 | 4.150% | 1,237 | 97.6400 | 4.3500% |
1.85% notes due 2020 | 1.850% | 1,232 | 98.5000 | 3.0900% |
2.35% notes due 2022 | 2.350% | 1,220 | 96.9000 | 3.3900% |
1.125% euro-denominated notes due 2021 | 1.125% | 1,185 | 103.0500 | 0.9000% |
1.875% euro-denominated notes due 2026 | 1.875% | 1,178 | 106.6100 | 1.0100% |
3.875% notes due 2021 | 3.875% | 1,140 | 101.1200 | 3.3700% |
2.40% notes due 2022 | 2.400% | 993 | 96.2900 | 3.4600% |
6.50% notes due 2033 | 6.500% | 729 | 138.4460 | 4.2735% |
0.50% euro-denominated notes due 2024 | 0.500% | 591 | 98.8200 | 0.7000% |
1.375% euro-denominated notes due 2036 | 1.375% | 587 | 94.2000 | 1.7600% |
2.50% euro-denominated notes due 2034 | 2.500% | 585 | 111.6900 | 1.6700% |
3.60% notes due 2042 | 3.600% | 489 | 99.2500 | 3.6327% |
6.55% notes due 2037 | 6.550% | 415 | 141.6800 | 4.3373% |
5.75% notes due 2036 | 5.750% | 338 | 116.5775 | 4.7940% |
5.95% debentures due 2028 | 5.950% | 306 | 121.7100 | 4.3910% |
5.85% notes due 2039 | 5.850% | 270 | 119.4500 | 4.7831% |
6.40% debentures due 2028 | 6.400% | 250 | 113.5100 | 5.3414% |
6.30% debentures due 2026 | 6.300% | 135 | 114.1305 | 5.0833% |
We need at least 10 more requests to produce the answer.
0 / 10 have requested this problem solution
The more requests, the faster the answer.
You work at Merck & Company (MRK), a well-known pharmaceutical company. Part of your job is...
can you help me with 1d and proper explanation of 2b CARP: CH14 Long-Term Debt (Part III of the Corporate Annual Report Project) NOTE: ALL DOCUMENTATION TO SUPPORT YOUR ANSWERS MUST COME FROM THE FINANCIAL STATEMENTS AND/OR THE NOTES TO THE FINANCIAL STATEMENTS. 1. Locate the financial statement that reveals to the reader the debt balances at fiscal year end February 2, 2019. a. On what page of the annual report does that statement appear? F-7 b. What dollar amount...
i need help with 1c and 2b. CARP: CH14 Long-Term Debt (Part III of the Corporate Annual Report Project) NOTE: ALL DOCUMENTATION TO SUPPORT YOUR ANSWERS MUST COME FROM THE FINANCIAL STATEMENTS AND/OR THE NOTES TO THE FINANCIAL STATEMENTS. 1. Locate the financial statement that reveals to the reader the debt balances at fiscal year end February 2, 2019. a. On what page of the annual report does that statement appear? F-7 b. What dollar amount does Macy's specifically report...
You are the director of operations for your company, and your vice president wants to expand production by adding new and more expensive fabrication machines. You are directed to build a business case for implementing this program of capacity expansion. Assume the company's weighted average cost of capital is 13%, the after-tax cost of debt is 7%, preferred stock is 10.5%, and common equity is 15%. As you work with your staff on the first cut of the business case,...
1. Alaa works for a pharmaceutical company that has developed a new drug. The patent on the drug will last 17 years. She expects that the drug’s profits will be $2 million in its first year and that this amount will grow at a rate of 5% per year for the next 17 years. Once the patent expires, other pharmaceutical companies will be able to produce the same drug and competition will likely drive profits to zero. What is the...
Hello, I am doing a WACC project of Apple, Inc and trying to follow the instruction below, but I do not think it is clear enough for me to follow. Calculating the Weighted Average Cost of Debt Find the market value of each bond issue. To do this find the number of bonds and then multiply by the price of the bond (remember that bond prices are quoted in 100s, but are really 1000s). If there is no bond price,...
Simply Cayenne Company: A Comprehensive Case In Measuring A Firm's Cost Of Capital (Boudreaux, D., S. Rao, and P. Das, 2014) THE CASE Patricia Hotard, the Chief Executive Officer of Simply Cayenne Refining and Processing Company (SCRPC), picked up the telephone to call Jimmy Breez, the firm's financial manager. Breez had sent her an email earlier that morning suggesting that the capital budgeting committee should get together prior to the scheduled Investment Decision Committee meeting that is in one week...
JOHNSON & JOHNSON AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF EARNINGS (Dollars and Shares in Millions Except Per Share Amounts) (Note 1)* 2016 71,890 21,789 50.101 20,067 9.143 29 Sales to customers Cost of products sold Gross profit Selling, marketing and administrative expenses Research and development expense In-process research and development Interest income Interest expense, net of portion capitalized (Note 4) Other (income) expense, net Restructuring (Note 22) Eamings before provision for taxes on income Provision for taxes on income (Note 8)...
JOHNSON & JOHNSON AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF EARNINGS (Dollars and Shares in Millions Except Per Share Amounts) (Note 1)* 2016 71,890 21,789 50.101 20,067 9.143 29 Sales to customers Cost of products sold Gross profit Selling, marketing and administrative expenses Research and development expense In-process research and development Interest income Interest expense, net of portion capitalized (Note 4) Other (income) expense, net Restructuring (Note 22) Eamings before provision for taxes on income Provision for taxes on income (Note 8)...
JOHNSON & JOHNSON AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF EARNINGS (Dollars and Shares in Millions Except Per Share Amounts) (Note 1)* 2016 71,890 21,789 50.101 20,067 9.143 29 Sales to customers Cost of products sold Gross profit Selling, marketing and administrative expenses Research and development expense In-process research and development Interest income Interest expense, net of portion capitalized (Note 4) Other (income) expense, net Restructuring (Note 22) Eamings before provision for taxes on income Provision for taxes on income (Note 8)...
JOHNSON & JOHNSON AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF EARNINGS (Dollars and Shares in Millions Except Per Share Amounts) (Note 1)* 2016 71,890 21,789 50.101 20,067 9.143 29 Sales to customers Cost of products sold Gross profit Selling, marketing and administrative expenses Research and development expense In-process research and development Interest income Interest expense, net of portion capitalized (Note 4) Other (income) expense, net Restructuring (Note 22) Eamings before provision for taxes on income Provision for taxes on income (Note 8)...